PMDA drug package insert

プラバスタチンNa錠5mg「NIG」

PMDA Prescription drug · 日医工岐阜工場株式会社 · package insert Feb 1, 2026

Key facts

Brand names プラバスタチンNa錠5mg「NIG」, プラバスタチンNa錠10mg「NIG」
Nonproprietary names プラバスタチンナトリウム
Companies 製造販売元/日医工岐阜工場株式会社, 販売元/日医工株式会社
Product type Prescription drug
Therapeutic category HMG-CoA還元酵素阻害剤 -高脂血症治療剤-
Therapeutic category codes 872189
YJ codes 2189010F1497, 2189010F2515
Approval numbers 22600AMX00732, 22600AMX00647
Package insert edition 第2版
Package insert date Feb 1, 2026
PMDA document key 581120_2189010F1497_1
PMDA company code 581120

At a glance

  • 1–9 Package insert revisions
  • 10–99 Related PMDA documents
  • None Safety communications
  • No PMDA review report published
  • No Risk management plan (RMP)

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMDA approved drugs and package inserts (Japan)

Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.

Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date:

Browse all PMDA approved drugs and package inserts (Japan)